Trial Profile
Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary) ; Vitamin D
- Indications Urticaria
- Focus Therapeutic Use
- 30 Apr 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 14 Mar 2017 New trial record